SCHEMBL7674670

SCHEMBL7674670

Cc1c2c(n(C)c1C(=O)c1ccc(Cl)cc1)CC(=O)O2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.41
PTGS2 P35354 1/20 0.41
CYP1A2 P05177 3/20 0.39
LMNA P02545 3/20 0.39
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTT P42858 4/20 0.39
MAPT P10636 4/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
POLB P06746 1/20 0.35
KMT2A Q03164 2/20 0.34
SRD5A2 P31213 1/20 0.34
MAPK1 P28482 1/20 0.34
HPGD P15428 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7674831 0.87 NPC1 (0.38) LMNAALDH1A1SMN1; SMN2TSHRHTT
SCHEMBL7677930 0.84 ALDH1A1 (0.34) ALDH1A1MAPT
SCHEMBL7678566 0.84 HTT (0.40) ABCB11PTGS2CYP1A2LMNAALDH1A1
SCHEMBL7678461 0.80 TSHR (0.47) CYP1A2ALDH1A1SMN1; SMN2TSHRMAPT
SCHEMBL7674449 0.78 ABCB11 (0.42) ABCB11PTGS2CYP1A2LMNAALDH1A1
SCHEMBL7678058 0.77 HTT (0.40) LMNAALDH1A1HTTMAPTCYP2C9
SCHEMBL8050588 0.76 PTGS2 (0.55) ABCB11PTGS2CYP1A2LMNAALDH1A1
SCHEMBL7675834 0.74 ABCB11 (0.41) ABCB11PTGS2CYP1A2LMNAALDH1A1
SCHEMBL8048118 0.73 PTGS2 (0.51) ABCB11PTGS2CYP1A2LMNAALDH1A1
SCHEMBL7676913 0.73 HTT (0.46) ABCB11PTGS2CYP1A2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A ABCB11 2317/4885PTGS2 887/4885CYP1A2 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.